Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.7699-0.0002 (-0.03%)
At close: 03:59PM EDT
0.7401 -0.03 (-3.87%)
After hours: 06:15PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close0.7701
Open0.7700
Bid0.7401 x 900
Ask0.7600 x 1100
Day's Range0.7421 - 0.7900
52 Week Range0.7400 - 2.6000
Volume40,736
Avg. Volume138,674
Market Cap20.935M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.7500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CANF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Can-Fite Biopharma Ltd Sponsore
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement